Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between December 20, 2019, and December 23, 2019. Jaguar Health, Inc., an emerging growth company incorporated in Delaware, reported the entry into material definitive agreements involving a private placement of equity securities and an exchange transaction with an existing investor.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: Approximately $1.5 million raised from the sale of approximately 2,500,000 shares of Common Stock and warrants to purchase 1,250,000 shares.
- Warrant Terms: Exercise price of $0.78 per share; exercisable beginning 6 months after closing and expiring 60 months after closing.
- Exchange Transaction: Oasis Capital, LLC exchanged pre-funded warrants for 10,165 shares of newly authorized Series B-2 Convertible Preferred Stock. No additional cash proceeds were generated from this specific exchange.
- Preferred Stock Conversion: Each Series B-2 Preferred Share is convertible into 190 shares of Common Stock, subject to a 9.99% beneficial ownership limitation.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. It focuses exclusively on capital raising and equity restructuring activities.
Material Changes and Transactions
- December 20, 2019: Entered into a Securities Purchase Agreement for a private placement of unregistered common stock and warrants.
- December 23, 2019: Executed an Exchange Agreement with Oasis Capital, LLC, converting remaining pre-funded warrants into Series B-2 Convertible Preferred Stock.
- December 23, 2019: Filed a Certificate of Designation with the State of Delaware to authorize the Series B-2 Convertible Preferred Stock.
- Lock-Up Agreement: Oasis Capital agreed to a six-month lock-up period on the Series B-2 Preferred Shares following the exchange transaction.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company agreed to file a registration statement on Form S-1 within 20 business days of the Purchase Agreement to register the resale of the Shares and Warrant Shares.
- Conversion Limitations: The Series B-2 Preferred Stock includes a beneficial ownership limitation preventing conversion if it would result in the holder owning more than 9.99% of outstanding Common Stock, unless the holder provides 61 days' prior notice to increase this limit.
- Voting Rights: Series B-2 Preferred Stock generally has no voting rights but retains veto power over changes to its own powers, preferences, or rights.
Investor Verification Checklist
- Verify the closing date and actual amount of proceeds received from the $1.5 million private placement.
- Confirm the filing date and status of the Form S-1 registration statement required for the resale of the private placement securities.
- Review the full text of the Series B-2 Certificate of Designation (Exhibit 3.1) to understand specific anti-dilution adjustments and conversion mechanics.
- Assess the impact of the 9.99% beneficial ownership limitation on the liquidity and convertibility of the Series B-2 Preferred Stock held by Oasis Capital.
- Monitor the six-month lock-up period expiration for Oasis Capital's Series B-2 Preferred Shares.